中药足浴辅助治疗痛经的有效性与安全性:系统评价与Meta分析
汇总结果显示,辅助CHF可显著改善总有效率(RR 1.18,95%CI 1.12–1.23,P<0.00001)、VAS评分(MD 0.88,95%CI 0.68–1.09,P<0.00001)等指标,且不良事件较少、远期效果更好、复发率更低。但纳入研究方法学质量欠佳,结论需更多高质量多中心RCT验证。
要点
- 中药足浴作为痛经辅助治疗可提高总有效率并降低VAS疼痛评分。
- 辅助CHF不良事件较少,远期效果更好且复发率更低。
- 纳入研究方法学质量欠佳,临床决策需结合高质量证据验证。
核心结论
- 当前证据提示中药足浴可能是痛经患者有效且安全的辅助疗法。
- 但纳入研究方法学质量欠佳,需更多设计良好的高质量多中心RCT进一步验证。
研究设计与样本
- 共纳入18项RCT、1484例痛经患者,采用Cochrane协作工具评估方法学质量,Review Manager 5.3进行定量合成。
主要发现
- 辅助CHF显著改善总有效率(RR 1.18,95%CI 1.12–1.23,P<0.00001)。
- 辅助CHF显著降低VAS疼痛评分(MD 0.88,95%CI 0.68–1.09,P<0.00001)。
- 辅助CHF显著改善CMSS评分(MD 3.61,95%CI 2.73–4.49,P<0.00001)。
- 辅助CHF显著改善症状评分(SMD 1.09,95%CI 0.64–1.53,P<0.00001)与中医证候量表评分(MD 3.76,95%CI 2.53–4.99,P<0.0001)。
- CHF不良事件较少,远期效果更好(RR 1.34,95%CI 1.11–1.63,P<0.01),复发率降低(RR 0.19,95%CI 0.09–0.39,P<0.0001)。
关键数值与推荐
- 总有效率RR 1.18(95%CI 1.12–1.23,P<0.00001)。
- VAS评分MD 0.88(95%CI 0.68–1.09,P<0.00001)。
- CMSS评分MD 3.61(95%CI 2.73–4.49,P<0.00001)。
- 症状评分SMD 1.09(95%CI 0.64–1.53,P<0.00001),中医证候量表评分MD 3.76(95%CI 2.53–4.99,P<0.0001)。
- 远期效果RR 1.34(95%CI 1.11–1.63,P<0.01),复发率RR 0.19(95%CI 0.09–0.39,P<0.0001)。
临床怎么用
- 中药足浴可作为痛经的辅助治疗选项,可能提高疗效并减少复发。
- 临床应用时应关注不良事件,并结合患者具体情况个体化使用。
- 鉴于纳入研究方法学质量欠佳,应审慎解读证据并期待更高质量研究验证。
局限性
- 纳入研究的方法学质量欠佳(desirable以下),可能影响结论可靠性。
- 需更多设计良好、高质量的多中心RCT进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal footbaths (CHF) as an adjunctive therapy in managing dysmenorrhea. METHODS: Ten electronic databases were searched to identify eligible randomized clinical trials (RCTs) from inception until June 2023. Outcome measurements encompassed the total effective rate, visual analog scale (VAS) score of pain intensity, Cox menstrual symptom scale (CMSS) score, symptom score, Traditional Chinese Medicine (TCM) syndrome scale, and any reported adverse events. The methodological quality of the included studies was assessed with the Cochrane collaboration tool. Review Manager 5.3 software was employed for quantitative synthesis, and funnel plots were utilized to evaluate potential reporting bias. RESULTS: Eighteen RCTs with 1,484 dysmenorrhea patients were included. The aggregated results suggested that the adjunctive CHF could significantly ameliorate dysmenorrhea, as evident from the improved total effective rate [risk ratio (RR) 1.18, 95% confidence interval (CI): 1.12 to 1.23, P < 0.00001], VAS (MD 0.88, 95% CI: 0.68 to 1.09, P < 0.00001), CMSS (MD 3.61, 95% CI: 2.73 to 4.49, P < 0.00001), symptom score (SMD 1.09, 95% CI: 0.64 to 1.53, P < 0.00001), and TCM syndrome scale (MD 3.76, 95% CI: 2.53 to 4.99, P < 0.0001). In addition, CHF presented fewer adverse events with a better long-term effect (RR 1.34, 95% CI: 1.11 to 1.63, P < 0.01) and diminished recurrence rate (RR 0.19, 95% CI: 0.09 to 0.39, P < 0.0001). CONCLUSION: Current evidence implies that CHF may be an effective and safe adjunctive therapy for patients with dysmenorrhea. However, the methodological quality of the studies included was undesirable, necessitating further verification with more well-designed and high-quality multicenter RCTs. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=188256, identifier registration number.
引用
- Tian X, Wei J, Zhuang Y, et al. Effectiveness and safety of Chinese herbal footbaths as an adjuvant therapy for dysmenorrhea: a systematic review and meta-analysis. Front Pharmacol. 2024. PMID: 39161905. doi:10.3389/fphar.2024.1397359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。